NeuroFrontiers

Recent developments in artificial intelligence (AI) technology have shown to aid with neurological disease diagnosis, risk stratification, treatment response, and more. So what are the newest AI applications? And perhaps even more importantly, what’s to come in the future? To find out the answer to these and other key questions, Dr. Jerome Lisk speaks with Dr. Mark Mintz, Chief Medical Officer and Founder of NeurAbilities Healthcare, to discuss emerging AI tools in the field of neurology.

Schizophrenia is a chronic mental disorder characterized by symptoms that negatively affect a patient’s mental and emotional behaviors. And although there are current treatment options including first and second-generation antipsychotics, treatment challenges still persist. That’s why Dr. Andrew Wilner speaks to psychiatrist Dr. Craig Chepke from Excel Psychiatric Associates to discuss clinical strategies that can help optimize outcomes for our patients.

Hypertension affects nearly half of adults in the United States and is associated with cognitive decline and dementia. A wide variety of antihypertensive medications are prescribed to millions of people to control blood pressure and prevent vascular dementia. Could it be that certain medications are better than others in preventing brain injury from chronic hypertension? Dr. Andrew Wilner is joined by Dr. Zachary Marcum, Associate Professor in the School of Pharmacy-University of Washington, to discuss his recent study investigating the association between certain hypertension medications and reduced cognitive impairment.

Increasing evidence indicates the involvement of B cells in the pathogenesis of multiple sclerosis (MS), but their exact role is unclear. Despite that uncertainty, B-cell depletion therapies have shown to ease symptoms, prevent relapses, and even slow the course of the disease. So how exactly do B-cell therapies work, and how do we know if they’re right for our patients? Joining Dr. Charles Turck to talk about the role of b-cell therapies for our MS patients is Dr. Andrew Chan.

Join us as examine the involvement of B cells in MS pathogenesis and the mechanisms that lead to B cell overactivation with Dr. Alessandro Didonna, Associate Professor of Neurology at UCSF Weill Institute for Neurosciences.

Although there’s still no cure for Alzheimer’s disease, we’ve made great strides in understanding the tragic disease that affects more than 50 million people worldwide. So what are the latest updates in treating and alleviating this disease? To learn more about what’s new in Alzheimer’s disease research, Dr. Jerome Lisk speaks with Dr. Peter Whitehouse and Dr. Daniel George, co-authors of American Dementia: Brain Health in an Unhealthy Society.

The FDA’s recent approval of aducanumab for the treatment of Alzheimer’s disease has been met with a controversial response. So what do we need to know about this new drug and its potential to treat this progressive neurological disorder? Dr. Jerome Lisk is joined by Dr. Peter Whitehouse from Case Western Reserve University to break down the approval of this new drug and what it could mean for patients.

Unfortunately, not all of our patients with multiple sclerosis (MS) respond well to treatment. That’s why it’s critical to constantly assess their response to treatment and notice the signs that someone might be an efficacy-challenged patient. But what exactly are those signs, and how can you go about switching therapies? Joining Dr. Hector Chapa to share key strategies for managing efficacy-challenged patients with MS is Dr. Ahmed Obeidat.

From therapeutic limitations to routes of administration, there’s a lot we need to keep in mind when selecting a treatment option for our patients with multiple sclerosis (MS). But it’s also just as important to consider patient-specific elements too, like their preferences and the socioeconomic factors affecting them. That’s why Dr. Ahmed Obeidat joins Dr. Hector Chapa to share these and other key treatment considerations in MS care.

What B-cell therapies are available for multiple sclerosis, and how do they fit into our treatment approach—in the context of the COVID-19 pandemic and beyond? Tune in to hear Dr. Charles Turck speak with Dr. Francesca Gilli about B-cell therapies.